AAO 2025: Jean-Francois Korobelnik, MD, shares highlights from the PULSAR extension study

Ahead of the 2025 American Academy of Ophthalmology (AAO) meeting in Orlando, Florida, the Eye Care Network spoke with Jean-Francois Korobelnik, MD. Prof Korobelnik, of Hôpital Pellegrin and CHU de Bordeaux, Bordeaux, France, is an editorial advisor for Modern Retina. This year, he is a co-author of a poster on the PULSAR extension study, assessing aflibercept as a therapy for neovascular, or wet, age-related macular degeneration (AMD). The research examined fluid resolution in treatment-naive patients with nAMD receiving aflibercept 8 mg, or those patients who were making a switch from 2 mg to 8 mg aflibercept. The full poster was presented by Marion Ronit Munk, MD, PhD, during the congress.

In this video, Prof Korobelnik discusses the fluid resolution outcomes observed in the study, describes the accompanying functional outcomes and patient response, addresses possible areas of future study and shares his perspective on the changing landscape of retinal therapies.